BAGNEUX, France--(BUSINESS WIRE)--Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a molecular diagnostics and technology company specialized in the development of single DNA detection tools for research and in vitro diagnostic, announced today that it was invited to hold a special symposium dedicated to the robustness of single-molecule techniques for DNA replication analysis. The presentation took place on September 6, 2017, during the broad-based DNA replication and Genome Maintenance meeting, hosted for over 10 years in Cold Spring Harbor (NYC, USA). Over 300 participants attended the event.
The workshop was introduced by Prof. Susan Gerbi (Brown University), the recipient of many awards for her research and a long-time collaborator of Genomic Vision. This introduction on fiber assays’ history and their evolution through time was followed by two short talks.
First, Erin Sybouts presented her PhD work conducted at the University of Texas Health Science Center at San Antonio in Dr Alex Bishop’s laboratory, and focused on the whole-genome analysis of replication fork defects by molecular combing in various genetic conditions. Then, Dr. Yannick Delpu presented his post-doctoral work conducted at the New York University in Dr Mamta Tahiliani’s laboratory about the benefits of Molecular Combing technology to address various critical issues, notably while studying replication at a specific locus.
“I am very encouraged to see the user-friendly tools being developed for combing. It is going to make the technology available to a lot more people and greatly expand the adoption of single molecule DNA replication technique,” declared Prof. Nicholas Rhind, University of Massachusetts Medical School.
Genomic Vision, represented by Dr Julien Cottineau, also presented a new version of its FiberStudio® software that meets the needs of its clients across various sectors such as academic research, drug discovery and gene editing industry and clinical diagnostics. Based on advanced image and data processing algorithms as well as recent Machine Learning approaches, FiberStudio® automatically detects, measures and classifies linear objects of stretched DNA molecules in order to provide users and clinicians with comprehensive reports showing complex structural variations, spatiotemporal analysis of DNA replication and a number of other applications.
“This first satellite symposium rewards our marketing efforts in the U.S. Our successful exposure to major KOL’s in the field of DNA replication demonstrates the potential of molecular combing technology to identify and counter damages in DNA replication that causes critical genetic alterations,” concluded Stephane Altaba, ýExecutive Vice-President Corporate Development at Genomic Vision.
ABOUT GENOMIC VISION GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong proprietary technology allowing to identify genetic abnormalities, GENOMIC VISION stimulates the R&D productivity of the pharmaceutical companies, the leaders of the diagnostic industry and the research labs. The Company develops a robust portfolio of diagnostic tests (breast, ovarian and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based near Paris, in Bagneux, the Company has approximately 60 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV - ISIN: FR0011799907). For further information, please visit www.genomicvision.com
Member of CAC® Mid & Small and CAC® All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.
Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section in its Document de Reference filed with the French Autorité des Marchés Financiers (AMF) on March 28, 2017, under number R.17-009, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.